Company Goals

• Acquire pharmaceutical candidates of exceptional commercial potential that are ready to enter or are already in early-stage clinical development
• Augment asset value by efficiently advancing development through the Phase II proof of concept stage; and
• Exit by partnering resultant Phase III-ready drugs with other pharmaceutical companies

Disease Focus

Neuropsychiatric disorders stand at the intersection of increasing medical need (as our population ages) and improving technical opportunity (due to the growth of neurosciences research). Nevertheless, translating advances in our understanding of normal and disordered nervous system function to the benefit of patients with neurologic and psychiatric disease has met with only limited success. Based on the extensive experience of our management team in this field, CPC stands poised to make significant contributions towards improving the pharmacotherapy of CNS disease.

Product Acquisition

CPC seeks to acquire direct ownership or a controlling stake in novel, differentiated, commercially attractive pharmaceutical candidates, generally those at or near clinical-stage development. Most products in our development pipeline result from our in-licensing activities. Nearly all originate at academic research centers, small biotechs, and other pharmaceutical companies, and are discovered as a consequence of the Company's well-established networks and surveillance capabilities in the CNS space. Each is selected on the basis of rigorous due diligence effort.

• Recognizing unmet medical need
• Exploiting emerging scientific opportunity
• Satisfying commercial imperatives

Although most acquisitions are new chemical entities, consideration is also given to older drugs where improvements in formulation can confer substantial advantages or where an exceptional repurposing potential exists without the risk of generic competition.

Product Development

Once the acquisition process has been completed, an experienced project management team assures the product's timely, regulatory and market driven development. The Company is committed to actively managing clinical development through the two to four years needed to complete Phase I (safety / tolerability / pharmacokinetic) evaluations and Phase II proof of concept studies.

Product Exit

At present, CPC plans to partner its Phase III ready products with third parties best able to provide the personnel and financial backing to realize their full market potential. Product exit will ordinarily occur within three to five years of acquisition, when the value inflection attending successful completion of Phase II proof of concept studies has been optimized.

Partnering

CPC operations depend on collaboration with others. We form alliances with individual researchers and research institutions as well as with pharmaceutical and biotechnology companies throughout the world to acquire product candidates for early stage development, and later to license these Phase III-ready assets out for final development and commercialization.